Want to see ACRV full AI Analyst Report?
Top Page
Acrivon Therapeutics, Inc.
(NASDAQ:ACRV)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-15.73% Downside)
Action:Reiterated
Date:06/18/26
The score is held down primarily by weak financial performance typical of a pre-revenue biotech (persistent losses and cash burn), with additional pressure from a bearish technical setup (price below key moving averages and negative MACD). Low leverage provides some balance-sheet support, and corporate updates are constructive on clinical progress, but dilution risk and limited valuation anchors keep the overall score below average.
Positive Factors
Proprietary precision platform (AP3)
Acrivon's AP3 proteomics platform is a durable competitive asset: biomarker-driven patient selection can raise trial success odds, enable targeted registrational strategies, and support companion diagnostics or partnerships, improving long-term development efficiency and differentiation.
Negative Factors
Pre-revenue with persistent cash burn
As a pre-revenue biotech, Acrivon records persistent negative operating and free cash flow, forcing reliance on external funding. Over 2-6 months this structural cash burn compresses runway if milestones slip and increases financing frequency and dilution risk for shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary precision platform (AP3)
Acrivon's AP3 proteomics platform is a durable competitive asset: biomarker-driven patient selection can raise trial success odds, enable targeted registrational strategies, and support companion diagnostics or partnerships, improving long-term development efficiency and differentiation.
Read all positive factors
Acrivon Therapeutics, Inc. (ACRV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$71.91M
Dividend YieldN/A
Average Volume (3M)996.44K
Price to Earnings (P/E)―
Beta (1Y)1.82
Revenue GrowthN/A
EPS Growth9.80%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,801,727
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit71.56
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$11.33Price Target Upside536.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.50M
Acrivon Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific med...
How the Company Makes Money
As a clinical-stage biotechnology company, Acrivon Therapeutics’ ability to generate recurring product revenue is not publicly evidenced; it typically would not have meaningful commercial sales until a drug is approved. null...
Acrivon Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 228.00K | -1.36M | -1.01M | -536.00K | 0.00 | 0.00 |
| EBITDA | -82.08M | -76.55M | -79.55M | -59.85M | -30.80M | -16.21M |
| Net Income | -77.27M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
Balance Sheet | ||||||
| Total Assets | 107.83M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Cash, Cash Equivalents and Short-Term Investments | 97.74M | 118.58M | 179.48M | 127.46M | 127.75M | 99.60M |
| Total Debt | 2.42M | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Total Liabilities | 12.32M | 17.20M | 19.80M | 17.07M | 10.75M | 130.40M |
| Stockholders Equity | 95.52M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
Cash Flow | ||||||
| Free Cash Flow | -66.29M | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Operating Cash Flow | -64.67M | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Investing Cash Flow | 60.01M | 66.10M | -51.77M | 50.72M | -141.68M | -238.00K |
| Financing Cash Flow | -439.00K | -749.00K | 121.03M | -1.55M | 101.71M | 112.22M |
Acrivon Therapeutics, Inc. Technical Analysis
Positive
1.78
Price Trends
1.72
Negative
1.65
Positive
1.86
Negative
Market Momentum
-0.02
Negative
56.64
Neutral
73.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Positive. The current price of 1.78 is above the 20-day moving average (MA) of 1.53, above the 50-day MA of 1.72, and below the 200-day MA of 1.86, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 56.64 is Neutral, neither overbought nor oversold. The STOCH value of 73.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRV.
Acrivon Therapeutics, Inc. Risk Analysis
Acrivon Therapeutics, Inc. disclosed 82 risk factors in its most recent earnings report. Acrivon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acrivon Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
ACRV
Acrivon Therapeutics, Inc.
1.78
0.55
44.72%
MNOV
Medicinova
1.32
0.05
3.94%
ALGS
Aligos Therapeutics
5.77
-1.62
-21.92%
GNTA
Genenta Science SpA Sponsored ADR
1.84
-1.98
-51.83%
IMMX
Immix Biopharma
10.31
8.12
370.78%
CAMP
CAMP4 Therapeutics Corporation
4.37
3.02
223.70%
Acrivon Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Acrivon Shareholders Approve Expanded Equity Plan and Directors
Positive
Jun 17, 2026
On June 17, 2026, Acrivon Therapeutics held its 2026 annual meeting of stockholders, where investors approved an amended and restated 2022 Equity Incentive Plan that expands the share pool to 8,606,723 shares, including an additional 3,000,000 sha...
Business Operations and StrategyFinancial Disclosures
Acrivon Highlights Positive ACR-368 Data and 2025 Results
Positive
Mar 19, 2026
On March 19, 2026, Acrivon Therapeutics reported fourth quarter and full-year 2025 results, highlighting progress in its registrational-intent Phase 2b trial of ACR-368 in endometrial cancer, including a 52% confirmed overall response rate in sero...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.